「code」の検索結果
18件：1～5件目を表示
-
ka, Japan; President: Mr. Shuhei Yoshida; hereinafter: Senju) is developing a compound (development code: SJP-0132) discovered by Mochida Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan; President...
https://www.senju.co.jp/system/files/content_news/2024-07/ENG_20240716_0.pdf -
n; President: Mr. Shuhei Yoshida; hereinafter: Senju) is developing a TRPV1 antagonist (development code: SJP-0132) discovered by Mochida Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan; President...
https://www.senju.co.jp/system/files/content_news/2025-01/ENG_20250117_0.pdf -
n; President: Mr. Shuhei Yoshida; hereinafter: Senju) is developing a TRPV1 antagonist (development code: SJP-0132) discovered by Mochida Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan; President...
https://www.senju.co.jp/system/files/content_news/2025-01/ENG_20250117.pdf -
sed to announce that “Avarept® Ophthalmic suspension 0.3%” (Generic Name: Motugivatrep, development code: SJP-0132, hereinafter: Product), discovered and licensed by Mochida Pharmaceutical Co., Ltd. (...
https://www.senju.co.jp/system/files/content_news/2025-12/ENG_20251222.pdf -
临床试验信息 | 研究与开发 | 千寿制药株式会社
nical Trial Summaries ※Listed in order of date of first publication Medical Condition Phase Project Code Country Recruitment Status Access to Trial ID Allergic Conjunctivitis 2 SJP-0049 Japan Complete...
http://www.senju.co.jp/chinese/rd/trial.html